Cancer immunotherapy, which is designed to empower a patient’s own immune system to eliminate cancer cells anywhere in the body, has produced cure-like remissions in very advanced cancers, including melanoma, lung cancer, and leukemia.
4-Jun-2015 1:05 PM EDT
The Cancer Research Institute (CRI) is proud to announce the addition of peer-to-peer advocacy, enhanced sharing functionality, and tumor type-specific information to TheAnswerToCancer.org (TheA2C), a first-of-its-kind website and online community...
3-Nov-2014 11:15 AM EST
The Cancer Research Institute (CRI) will host its 22nd Annual International Cancer Immunotherapy Symposium October 6-8, 2014, at The Grand Hyatt in New York City.
3-Oct-2014 6:05 PM EDT
The Cancer Research Institute announced today the winners of the 2014 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.
16-Sep-2014 3:00 PM EDT
Cancer Research Institute to Bestow Top Scientific Prize for Breakthrough Discoveries in Cancer Immunotherapy
CRI honors four scientists for their collective contributions to the discovery and elucidation of the PD-1 receptor pathway as a therapeutic target in cancer treatment.
1-Aug-2014 3:00 PM EDT
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer...
24-Apr-2013 9:00 AM EDT
Mitchell H. Gold, M.D., has been elected to the Board of Trustees of the nonprofit Cancer Research Institute. Dr. Gold is chairman, chief executive officer, and founder of Alpine Biosciences, a privately held, Seattle-based biotech company dedicated...
15-Oct-2012 8:00 AM EDT
MedImmune, the global biologics arm of AstraZeneca, has signed a collaboration with two nonprofits, the Cancer Research Institute and Ludwig Institute for Cancer Research, to advance clinical development of cancer immunotherapy
9-Oct-2012 9:00 AM EDT
The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a...
7-Aug-2009 9:00 AM EDT
Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in...
29-Apr-2009 11:20 AM EDT